Tuesday, Aug. 14th, 2017, London, UK: Biogerontology Research Foundation (BGRF) Chief Science Officer Alex Zhavoronkov and BGRF Trustee Jim Mellon announce a multi-year drug development agreement, whereby Juvenescence Limited (led by Jim Mellon) will utilize leads generated by Insilico Medicine (led by Dr. Zhavoronkov) through their deep-learned drug discovery engines to develop drugs aiming to treat aging and age-related diseases, as well as a set of companion multi-modal age-related disease biomarkers.
Insilico Medicine has spent several years developing and refining their deep-learned drug discovery engines to predict the biological activity of compounds based on deep-learned training on structural, functional and phenotypic data. Insilico's team has strove to incorporate the newest AI techniques, such as Generative Adversarial Networks (GANs), into their drug discovery platforms in an effort to position themselves as a leader of AI-based drug discovery and development, with the capability to generate novel compounds with specifiable pharmacokinetic and pharmacodynamic properties via deep learning alone, thereby drastically accelerating the time and expense invested into novel drug discovery and development.
"The team at Juvenescence is very excited to partner with Insilico Medicine to tackle
Insilico Medicine was the first company to apply GANs to the task of generating novel molecular structures with specifiable parameters, and have published several proof-of-concept studies on the application of deep neural networks to
"The application of deep learning to
This agreement between Juvenescence and Insilico has led to the formation of a new joint venture, Juvenescence AI, to serve as a vehicle for the real-world validation of Insilico's deep-learned leads. As part of the deal, Juvenescence AI has agreed to
"Given the increasing cost of drug discovery, development and clinical evaluation, it is clear that the clinical translation of
About the Biogerontology Research Foundation
The Biogerontology Research Foundation is a UK non-profit research foundation and public policy center seeking to fill a gap within the research community, whereby the current scientific understanding of the ageing process is not yet being sufficiently exploited to produce effective medical interventions. The BGRF funds and conducts research which, building on the body of knowledge about how ageing happens, aims to develop biotechnological interventions to remediate the molecular and cellular deficits which accumulate with age and which underlie the ill-health of old age. Addressing ageing damage at this most fundamental level will provide an important opportunity to produce the effective, lasting treatments for the diseases and disabilities of ageing, required to improve quality of life in the elderly. The BGRF seeks to use the entire scope of modern biotechnology to attack the changes that take place in the course of ageing, and to address not just the symptoms of age-related diseases but also the mechanisms of those diseases.
About Juvenescence Limited
Juvenescence Limited is an investment company focussed on therapies to increase human longevity and complementary investments in related sectors. It was founded in 2017 by Jim Mellon, Greg
Juvenescence believes that advances in science have made real the possibility of slowing, halting or potentially reversing some elements of
About Juvenescence AI Limited
Juvenescence AI Limited is a drug development and artificial intelligence company focussed on
About Insilico Medicine, Inc
Insilico Medicine, Inc. is an artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D resources in Belgium, Russia, and the UK sourced through hackathons and competitions. The company